Induction of propranolol metabolism in isolated rats hepatocytes treated by di(2-ethylhexyl) phthalate (DEHP) and mono(2-ethylhexyl) phthalate (MEHP)

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 3, 2003, Pages 217-222

  Kambia, K ^a   Dine, T ^a   Gressier, B ^a   Benaji, B ^b   Faouzi, M A ^c   Dupin Spriet, T ^a   Luyckx, M ^a   Brunet, C ^a  

^a UNIV LILLE   (France)

^b HASSAN II UNIVERSITY   (Morocco)

^c MOHAMMED V UNIVERSITY   (Morocco)

Author keywords

DEHP; Dialyzed patients; Hepatocytes; MEHP; Metabolisation

Indexed keywords

CYTOCHROME P450; PHENOBARBITAL; PHTHALIC ACID 2 ETHYLHEXYL MONOESTER; PHTHALIC ACID BIS(2 ETHYLHEXYL) ESTER; PLASTICIZER; POLYVINYLCHLORIDE; PROPRANOLOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG METABOLISM; ENZYME INDUCTION; HEMODIALYSIS PATIENT; IN VIVO STUDY; LEACHING; LIVER CELL; LIVER METABOLISM; MALE; NONHUMAN; PEROXISOME; PREDICTION; RAT; RAT STRAIN; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS; XENOBIOTIC METABOLISM;

EID: 0141848482     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03190488     Document Type: Article

References (25)

1. Christensson A., Ljunggren L., Nilsson-Thorell C., Arge B., Diehl U., Hagstam K.E., Lundberg M. (1991): In vivo comparative evaluation of hemodialysis tubing plasticized with DEHP and TEHTM. Int. J. Art. Organs, 14, 407-410.
2. Okita R.T., Okita J.R. (1992): Characterization of a Cytochrome P450 from Di(2-ethylhexyl) phthalate-treated rats which hydroxylates fatty acids. Arch. Biochem. Biophys., 294, 475-481.
3. Gebel T., Arand M., Oesch F. (1992): Induction of the peroxisome proliferator-activated receptor by fenofibrate in rat liver. FEBS., 309, 37-40.
4. Isseman I., Green S. (1990): Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 347, 645-650.
5. Conway J.G., Tomaszewski K.E., Olson M.J., Cattley R.C., Marsman D.S., Popp J.A. (1989): Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl) phthalate and Wy-14,643. Carcinogenesis, 10, 513-519.
6. Cattley R.C., De Luca J., Elcombe C., Fenner-Crisp P., Lake B.G., Marsman D.S., Pastoor T.A., Popp J.A., Robinson D.E., Schwetz B., Tugwood J., Wahli W. (1998): Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans? Regul. Toxicol. Pharmacol., 27, 47-60.
7. Lake B.G. (1995): Mechanisms of hepatocarcinogenicity of peroxisome-proliferating drugs and chemicals. Annu. Rev. Pharmacol. Toxicol., 35, 483-507.
8. Doull J., Cattley R., Elcombe C., Lake B.G., Swenberg J., Wilkinson C., Williams G., Van Gemert M. (1999): A cancer risk assessment of di(2-ethylhexyl) phthalate: Application of the New U.S. EPA risk assessment guidelines. Regul. Toxicol. Pharmacol., 29, 327-357.
9. Tanaka T. (2002): Reproductive and neurobehavioural toxicity study of bis(2-ethylhexyl) phthalate (DEHP) administered to mice in the diet. Food Chem. Toxicol., 40, 1499-1506.
10. Park J.D., Habeebu S.M., Klaasen C.D. (2002): Testicular toxicity of Di(2-Ethylhexyl) Phthalate in young Sprague-Dawley rats. Toxicology, 171, 105-115.
11. Moore R.W., Rudy T.A., Lin T.M., Ko K., Peterson R.E. (2001): Abnormalities of sexual development in male rats with in utero and lactation exposure to the antiandrogenic plasticizer Di(2-Ethylhexyl) Phthalate. Environ. Health Perspect., 109, 229-237.
12. Akingbemi B.T., Youker R.T., Sottas C.M., Ge R., Katz E., Klinefelter G.R., Zirkin B.R., Hardy M.P. (2001): Modulation of rat leydig cell steroidogenic function by Di(2-Ethylhexyl) Phthalate. Biol. Reprod., 65, 1252-1259.
13. Pollack G.M., Buchanan J.F., Slaughter R.L., Kohli R.K., Shen D.D. (1985): Circulating concentrations of DEHP and its de-esterified phthalic acid products following plasticizer exposure in patients receiving hemodialysis. Toxicol. Appl. Pharmacol., 79, 257-267.
14. Faouzi MA., Dine T., Gressier B., Kambia K., Luyckx M., Pagniez D., Brunet C., Cazin M., Belabed A., Cazin J.C. (1999): Exposure of hemodialysis patient to di(2-ethylhexyl) phthalate. Int. J. Pharm., 180, 113-121.
15. Chu I.H., Villeneuve D.C., Secours V., Franklin C., Rock G., Viau A. (1977): Metabolism and tissue distribution of MEHP in the rat. Drug Metab. Dispos., 6, 146-149.
16. Sjöberg P., Bondesson U., Hammarlund M. (1985): Non linearities in the pharmacokinetics of di(2-ethylhexyl) phthalate and metabolites in male rats. Arch. Toxicol., 58, 72-77.
17. Moldéus, P., Hogberg J., Orrenius S. (1978): Isolation and use of liver cells. Meth. Enzymol., 52, 60-71.
18. Guillouzo C., Guillouzo A. (1986): Methods for preparation of adult and fetal hepatocytes. In: Guillouzo A., Gueguen-Guillouzo C., (eds). Isolated and cultured hepatocytes. Paris: les Editions INSERM, and London. John Libbey Eurotext 1-12.
19. Chiu F.C.K., Raymond K. (1996): Validated assay for the determination of celiprolol in plasma using HPLC and a silanol deactivated reverse-phase support. J. Chromatogr. B., 687, 462-465.
20. Ring J.A., Ghabrial H., Ching M.S., Shulkes A., Smallwood R.A., Morgan D.J. (1995): Fetal hepatic propranolol metabolism. Studies in the isolated perfused fetal sheep liver. Drug Metab. Dispos., 23, 190-196.
21. Ereshefsky (1996): SSRI drug interactions and the cytochrome P450 system. J. Clin. Psychiatry, 57 (suppl 8), 17-25.
22. Pineau T, Galtier P., Bonfils C., Derancourt J., Maurel P. (1990): Purification of a sheep liver cytochrome P450 from the P450 IIIA gene subfamily. Its contribution to the N-dealkylation of veterinary drugs. Biochem. Pharmacol., 39, 901-909.
23. Murray M. (1992): Participation of a cytochrome P450 enzyme from the 2C subfamily in progesterone 21-hydroxylation in sheep liver. J. Steroid Biochem. Mol. Biol., 43, 591-593.
24. Yoshimoto K., Echizen H., Chiba K., Tani M., Ishizaki T. (1995): Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers-N-des-isopropylation is mediated mainly by CYP1A2. Br. J. Clin. Pharmacol., 39, 421-431.
25. Johnson J.A., Herring V.L., Wolfe M.S., Relling M.V. (2000): CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J. Pharmacol. Exp. Ther., 294, 1099-1105.